Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold. 2018

Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
Maulana Azad P. G. and Research Centre, Dr. Rafiq Zakaria Campus, Rauza Baug, Aurangabad 431001, India. urjasatish@gmail.com.

A series of ten novel derivatives of 4-(benzyloxy)-N-(3-chloro-2-(substituted phenyl)-4-oxoazetidin-1-yl) benzamide 6a⁻j were synthesized in good yield from the key compound 4-(benzyloxy)-N'-(substituted benzylidene) benzo hydrazide, called Schiff 's bases 5a⁻j, by Staudinger reaction ([2 + 2] ketene-imine cycloaddition reaction) with chloro acetyl chloride in the presence of catalyst tri ethylamine and solvent dimethyl formamide (DMF), by using ultra-sonication as one of the green chemistry tools. All the synthesised compounds were evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis (MTB) and most of them showed promising activity with an IC50 value of less than 1 µg/mL. To establish the safety, all the synthesized compounds were further tested for cytotoxicity against the human cancer cell line HeLa and all 6a⁻j compounds were found to be non-cytotoxic in nature. The molecular docking study was carried out with essential enzyme InhA (FabI/ENR) of Mycobacterium responsible for cell wall synthesis which suggests that 6a and 6e are the most active derivatives of the series. The theoretical evaluation of cell permeability based on Lipinski's rule of five has helped to rationalize the biological results and hence the synthesized azetidinone derivatives 6a⁻j were also analyzed for physicochemical evaluation that is, absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties and the results showed that all the derivatives could comply with essential features required for a potential lead in the anti-tubercular drug discovery process.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069453 Ultrasonic Waves Oscillating sound wave with a frequency higher than the upper limit of the human hearing range. LIPUS,Low Intensity Pulsed Ultrasound,Low Intensity Pulsed Ultrasound Radiation,Low-Intensity Pulsed Ultrasound (LIPUS),Pulsed Ultrasound,Ultrasonic Vibration,Ultrasound Radiation,Ultrasound Waves,Low Intensity Pulsed Ultrasound (LIPUS),Low-Intensity Pulsed Ultrasounds (LIPUS),Pulsed Ultrasound, Low-Intensity (LIPUS),Pulsed Ultrasounds,Pulsed Ultrasounds, Low-Intensity (LIPUS),Radiation, Ultrasound,Ultrasonic Vibrations,Ultrasonic Wave,Ultrasound Wave,Ultrasound, Low-Intensity Pulsed (LIPUS),Ultrasound, Pulsed,Ultrasounds, Low-Intensity Pulsed (LIPUS),Ultrasounds, Pulsed,Vibration, Ultrasonic,Vibrations, Ultrasonic,Wave, Ultrasonic,Wave, Ultrasound,Waves, Ultrasonic,Waves, Ultrasound
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001384 Azetidines
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial

Related Publications

Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
September 2009, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
July 2012, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
January 2012, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
September 2008, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
June 2008, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
January 2012, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
March 2020, RSC advances,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
May 2020, RSC advances,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
November 2011, Acta crystallographica. Section E, Structure reports online,
Urja D Nimbalkar, and Julio A Seijas, and Rachna Borkute, and Manoj G Damale, and Jaiprakash N Sangshetti, and Dhiman Sarkar, and Anna Pratima G Nikalje
October 2009, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!